ENOV Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 02, 2026
Report Source: 2025 Annual Report
Enovis Corp. Stock Analysis ENOV
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Read More Enovis Corp (ENOV) Chart
Key Statistics of Enovis Corp (ENOV)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$25.89Volume
1.26MP/E Ratio (TTM)
-52 Week Range
Market Cap
1.38BAvg. Volume
1.12MDividend Yield
-Financial Metrics & Statements of Enovis Corp (ENOV)
FAQ's for Enovis Corp (ENOV)
- According to Musaffa’s Shariah screening methodology, Enovis Corp (ENOV) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.